A double-blinded, placebo-controlled randomized trial evaluating the efficacy and safety of Zhigancao Tang granules for treating HFpEF: study protocol for a randomized controlled trial

Na Zhang, Yingli Zhao, Yu Liu, Nuo Tang, Wang Zheng, Meijiao Mao, Qingcheng Liu, Lin Shen, Bing Deng, Na Zhang, Yingli Zhao, Yu Liu, Nuo Tang, Wang Zheng, Meijiao Mao, Qingcheng Liu, Lin Shen, Bing Deng

Abstract

Background: Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome characterized by diastolic dysfunction. Despite the increasing incidence of HFpEF, there is no available therapy that reduces the mortality rate of HFpEF. Zhigancao Tang has been used traditionally for the treatment of cardiovascular diseases in China. The use of traditional Chinese medicine (TCM) is associated with improvements in clinical syndromes and quality of life of patients. A randomized clinical trial should be conducted to provide clear evidence regarding the efficacy and safety of Zhigancao Tang granules for the treatment of HFpEF.

Methods: A randomized, double-blinded, placebo-controlled clinical trial was proposed. A total of 122 patients with HFpEF will be randomly assigned to receive Zhigancao Tang granules or placebo for 12 weeks. The primary outcome measure is cardiac function. The secondary outcomes include measurement of the integral TCM syndrome score, echocardiography, 6-min walk test, N-terminal-pro hormone B-type natriuretic peptide level, atrial natriuretic peptide level, Minnesota Living with Heart Failure scale, and Lee's scale. The outcome measures will be evaluated at baseline, 4 weeks, and 12 weeks. Adverse events will be evaluated from baseline till the 12-week follow-up period.

Discussion: The results of this trial will demonstrate whether Zhigancao Tang granules are effective and safe for treating HFpEF.

Trial registration: ClinicalTrials.gov NCT04317339 . Registered on 23 March 2020.

Keywords: Heart failure with preserved ejection fraction; Randomized controlled trial; Traditional Chinese medicine; Zhigancao Tang.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow diagram of the study process

References

    1. Gladden JD, Linke WA, Redfield MM. Heart failure with preserved ejection fraction. Pflugers Arch Eur J Physiol. 2014;466(6):1037–1053. doi: 10.1007/s00424-014-1480-8.
    1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016;18(8):2129. doi: 10.1093/eurheartj/ehw128.
    1. Andersson C, Vasan RS. Epidemiology of heart failure with preserved ejection fraction. Heart Fail Clin. 2014;10(3):377–388. doi: 10.1016/j.hfc.2014.04.003.
    1. Redfield MM. Heart failure with preserved ejection fraction. New Engl J Med. 2017;376(19):897.
    1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;128(16)62:e147–239.
    1. Xian S, Yang Z, Lee J, et al. A randomized, double-blind, multicenter, placebo-controlled clinical study on the efficacy and safety of Shenmai injection in patients with chronic heart failure. J Ethnopharmacol. 2016;186:136–142. doi: 10.1016/j.jep.2016.03.066.
    1. Wang J, Shi J, Wei J, et al. Safety and efficacy of Qishen granules in patients with chronic heart failure: study protocol for a randomized controlled trial. Trials. 2017;18(1):468. doi: 10.1186/s13063-017-2193-z.
    1. Sun J, Wugeti N, Mahemuti A. Reversal effect of Zhigancao decoction on myocardial fibrosis in a rapid pacing-induced atrial fibrillation model in New Zealand rabbits. J Int Med Res. 2019;49(2)884-92.
    1. Liu W, Xiong X, Feng B, et al. Classic herbal formula Zhigancao Decoction for the treatment of premature ventricular contractions (PVCs): a systematic review of randomized controlled trials. Complement Ther Med. 2015;23( 1):100-15.
    1. Chai C, Kou J, et al. Mice exposed to chronic intermittent hypoxia simulate clinical features of deficiency of both Qi and Yin syndrome in traditional Chinese medicine. Evid Based Complement Alternat Med. 2011;2011:356252. doi: 10.1093/ecam/nep226.
    1. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;29(4):277–314.
    1. Mogle J, Buck H, et al. Cross-validation of the Minnesota Living With Heart Failure Questionnaire. J Nurs Sch. 2017; 00:0,1–8.
    1. Cheng Xiaohan. Effect of promoting blood circulation and benefiting water on diastolic function in patients with left ventricular ejection fraction retention heart failure. Heilongjiang University of traditional Chinese Medicine, 2014.
    1. Butler J, Fonarow GC, Zile MR, et al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. Other. 2014;2(2).[J]. Jacc Heart Failure. 2014;2( 2):97-112.
    1. Ho JE, Enserro D, Brouwers FP, et al. Predicting heart failure with preserved and reduced ejection FractionCLINICAL PERSPECTIVE: the international collaboration on heart failure subtypes. Circ Heart Fail. 2016;9(6):e003116. doi: 10.1161/CIRCHEARTFAILURE.115.003116.
    1. Gurwitz JH, Magid DJ, Smith DH, et al. Contemporary prevalence and correlates of incident heart failure with preserved ejection fraction. Am J Med. 2013;126(5):393–400. doi: 10.1016/j.amjmed.2012.10.022.
    1. Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175(6):996–1004. doi: 10.1001/jamainternmed.2015.0924.
    1. Ferreira P, et al. Echocardiographic diastolic function evolution in patients with an anterior Q-wave myocardial infarction: insights from the REVE-2 study. ESC Heart Fail. 2019;6:70-9.
    1. Bouthoorn S, Valstar GB, Gohar A, et al. The prevalence of left ventricular diastolic dysfunction and heart failure with preserved ejection fraction in men and women with type 2 diabetes: a systematic review and meta-analysis. Diabetes Vasc Dis Res. 2018;15(6):477–493. doi: 10.1177/1479164118787415.
    1. Cleland JGF, et al. fast track: The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338–2345. doi: 10.1093/eurheartj/ehl250.
    1. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):0–781. doi: 10.1016/S0140-6736(03)14285-7.
    1. Investigators T S Irbesartan in patients with heart failure and preserved ejection fraction. Curr Cardiovasc Risk Rep. 2009;3(5):311–312. doi: 10.1007/s12170-009-0056-1.
    1. Kumar N, Garg N. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;371(2):179–182. doi: 10.1056/NEJMc1405715.
    1. Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction. JAMA. 2013;309(8):781. doi: 10.1001/jama.2013.905.
    1. Veldhuisen DJV, Cohen-Solal A, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure) J Am Coll Cardiol. 2009;53(23):2150–2158. doi: 10.1016/j.jacc.2009.02.046.
    1. Tong Y-q, Sun, et al. Changes of QT dispersion in hemodialysis patients after administrating Zhigancao decoction. Chin J Integr Med. 2018;24(08):69–73. doi: 10.1007/s11655-016-2599-6.
    1. Xiong X-J. Exploration on connotation of Zhigancao Decoction formula syndrome from the perspective of modern pathophysiology and severe cases of critical care and its clinical efficacy on cardioversion, maintenance of sinus rhythm, hemostasis, increasing platelets count, and tonifying deficiency. Zhongguo Zhong Yao Za Zhi. 2019;44:3842–3860.
    1. Yu-Chiang H, Ying-Jung T, Wen-Long H, et al. Demographic and prescribing patterns of Chinese herbal products for individualized therapy for ischemic heart disease in Taiwan: population-based study. PLoS One. 2015;10(8):e0137058. doi: 10.1371/journal.pone.0137058.
    1. Wu B-Y, Liu C-T, Chen S-Y, Tsai M-Y. A case of chemotherapy-induced congestive heart failure successfully treated with Chinese herbal medicine. Complement Ther Med. 2015;23(2):251–256. doi: 10.1016/j.ctim.2015.01.006.
    1. Tsai MY, Hu WL, Lin CC, et al. Prescription pattern of Chinese herbal products for heart failure in Taiwan: a population-based study. Int J Cardiol. 2017;228:90–96. doi: 10.1016/j.ijcard.2016.11.172.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel